Doxorubicin Hydrochloride Liposome Injection
制剂 FDF · Injection · 20mg/10ml
制剂 FDFConfidentiality：公开
- INN / Generic Name
- Doxorubicin Hydrochloride Liposome Injection
- Dosage Form
- Injection
- Strength
- 20mg/10ml
- Therapy Area
- Oncology
- Indication
- Breast cancer; Ovarian cancer; AIDS-related Kaposi's sarcoma; Multiple myeloma
- Current Status
- 官方 FDF 授权目录（UB857）
- GMP Certification
- CN - NMPA; US - FDA
- CEP
- No
- DMF Type
- —
- Stability Data
- —
- BE Required
- Not required / waivable
- Registration Pathway
- 已完成注册（目标市场可转移 / 视市场 DCP·NP）
- MOQ
- 询价
- Lead Time
- 询价
- Price Range
- 询价
Registrable Markets
China
Process / Sequence / Exact Price
- Process Summary
- —
- Exact Price
- —